The healthcare sector today was mostly bearish. One stock that has been particularly bearish over the last several days is Bristol-Myers Squibb (BMY). The stock is down from around $63.00 on October 9th to under $51.00 today. Part of this was due to the overall weakness in the healthcare sector, but compounding the decline is the fact that BMY is losing ground to Merck on first-line lung cancer treatment. For this reason and others, Citigroup downgraded the stock and gave it a $57 price target. Here’s a recap of what happened.

about the author:

Mike Patton

Mike Patton took the leap into the markets beginning as a commodities broker in 2005, where he was responsible for identifying trading opportunities and executing trades on behalf of clients. After years as a broker he made the jump to education by joining the team at Trading Advantage, now Prosper Trading Academy.

Read Similar Articles

April 6, 2026

Q1 Earnings Season Preview: What To Expect

As we start a brand new quarter in 2026, it also resets the earnings cycle for companies to report their quarterly results — and I believe that Q1 Earnings Season could have a lot in store. Q4 earnings season at the start of the year gave traders a lot to process. It also set the […]

Read Article
April 3, 2026

March 2026 Jobs Report: The Good, Bad, & Unexpected

The March 2026 Jobs Report was among the most anticipated ones in recent memory. Right now, the economy is being shaped by a number of factors: These current circumstances — combined with February’s bad jobs report — had traders preparing for the worst. Fortunately, the March 2026 Jobs Report looked much better than expected…at least […]

Read Article
January 21, 2026

Could Penny Stocks Be The Big Play In 2026?

Written By: Howard Greenberg As everyday traders put their trading plans into action for 2026, penny stocks might not be on many of their radars. It’s totally understandable why penny stocks may not appeal to the more calculated seasoned traders. Their reputations for susceptibility to manipulation, extreme volatility, and low liquidity make them way too […]

Read Article

Read Similar Articles

https://www.prospertrading.com/is-it-time-to-buy-msft/Is It Time to Buy MSFT?
April 13, 2026

Is It Time to Buy MSFT?

Like most tech names, Microsoft (MSFT) has seen a major decline in 2026. Since January, the stock was down over 24% at one point.   Although it’s made modest gains — climbing more than 7% — since hitting a new low in 2026, many traders are still wary. Mike Shorr covered this topic when he guest […]

Read Article
https://www.prospertrading.com/0dte-options-charlie-breaks-down-overnight-winner-in-avgo/0DTE Options: Charlie Breaks Down Overnight Winner In AVGO
April 10, 2026

0DTE Options: Charlie Breaks Down Overnight Winner In AVGO

On Thursday, Charlie Moon released his latest round of 0DTE options trade signals for his Thursday Blitz Program. A few of them were winners by Friday morning — +288%* in AMZN, +189%* in AMD… But his biggest results were in AVGO. Here’s the 0DTE options trade signal Charlie released: The results? A 552%* gain overnight! […]

Read Article
https://www.prospertrading.com/top-8-detractors-in-the-sp-500/Top 8 Detractors In The S&P 500
April 10, 2026

Top 8 Detractors In The S&P 500

The S&P 500 has faced some intense volatility in 2026. After falling more than 8% earlier this year, the index rallied over 7.5% since March 30th. While its resilience is noted, the underlying numbers show what’s really happening under the hood in the S&P 500. In reality, the index is largely influenced by a core […]

Read Article